For adults with type 2 diabetes mellitus (T2DM), bofanglutide, a glucagon-like peptide-1 receptor agonist, is associated with meaningful reductions in hemoglobin A1C (HbA1c) levels compared to ...

An elevated polygenic risk score may serve as a prognostic biomarker for identifying patients with open-angle glaucoma who are predisposed to rapid visual field decline. A higher polygenic risk score ...

Greater variation in systolic blood pressure between visits predicts visual field progression in primary open-angle glaucoma. In primary open-angle glaucoma (POAG), long-term variability in systolic ...

Compared with patching alone, combining an eye tracking-based video game therapy with traditional occlusion therapy yields superior posttreatment visual acuity in both the amblyopic and fellow eyes of ...

As vaccination rates drop nationwide, the virus is moving beyond insulated communities, overwhelming public health departments constrained by shoestring budgets. HealthDay News — Ben Dowse hadn’t ...

Few patients with stroke or traumatic brain injury (TBI) receive inpatient rehabilitation facility (IRF) care after hospitalization. HealthDay News — Few patients with stroke or traumatic brain injury ...

In 122 studies of fast progressing glaucoma, 88 different definitions of fast progression were used. There is substantial variation in the definition of “fast progressing glaucoma” across studies, ...

A systematic review and meta-analysis shows 0.01% to 0.05% atropine can effectively manage myopia progression. Low-dose atropine at 0.01% to 0.05% may be effective at slowing progression of myopia ...

Under new billing codes that take effect in January, doctors who manage maternity care will start charging à la carte for visits and services related to pregnancy, childbirth and postpartum care.

Combining an ultrasonic atomization of traditional Chinese medicinal herbs with artificial tears improves outcomes in dry eye disease compared with artificial tears alone. Chinese herbal medicine ...

The Food and Drug Administration (FDA) has approved Ranluspec ™ (ranibizumab-hkdz), an interchangeable biosimilar for Lucentis ®. Ranluspec is a vascular endothelial growth factor inhibitor indicated ...

Predominantly peripheral lesions serve as an objective clinical biomarker to identify individuals with diabetes who carry an elevated risk for secondary vision loss. The presence of predominantly ...